Analyst John Young CFA from Canaccord Genuity maintained a Buy rating on AngioDynamics and keeping the price target at $17.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
John Young CFA has given his Buy rating due to a combination of factors that highlight AngioDynamics’ promising growth prospects. The company has set an optimistic revenue guidance for FY26, projecting significant growth in its Med-Tech business, particularly in its Mechanical Thrombectomy franchise, which is expected to generate over $50 million in revenue. This growth is supported by the anticipated expansion of the AlphaVac and Auryon products, with Auryon expected to penetrate further into the hospital outpatient setting, which offers higher reimbursement rates.
Additionally, AngioDynamics’ NanoKnife technology is poised for growth with the introduction of new reimbursement codes in 2026, which should enhance its appeal to urologists treating intermediate prostate cancer. The management’s strategic focus on expanding the use of its technologies for other medical indications, such as coronary arteries and deep vein thrombosis, further underscores the company’s potential for sustained growth. These factors collectively contribute to John Young’s positive outlook and Buy rating for AngioDynamics’ stock.
Young CFA covers the Healthcare sector, focusing on stocks such as Merit Medical Systems, AngioDynamics, and Staar Surgical. According to TipRanks, Young CFA has an average return of -9.6% and a 32.35% success rate on recommended stocks.